Highlights•A multi-disciplinary team approach is recommended to optimize the management of Ovarian cancer.•Primary cytoreduction by experts is advised; if unfeasible to opt for neoadjuvant therapy then interval debulking surgery.•PARP inhibitors are recommended as a standard of care maintenance therapy in newly diagnosed advanced ovarian cancer.•Early genetic testing is primordial and helps dictate treatment decisions in newly diagnosed advanced ovarian cancer.•PARP inhibitors are recommended as maintenance therapy for platinum-sensitive relapse regardless of BRCA mutation status.